Outcomes | FBG/HbA1c | n | Events, n (%) | Crude OR (95% CI) | p Value | Adjusted OR (95% CI) | p Value |
---|---|---|---|---|---|---|---|
Secondary outcomes: during hospitalization | |||||||
 Infectious complicationsa | Q1 (≤ 0.81) | 214 | 21 (9.8) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 212 | 23 (10.8) | 1.12 (0.60–2.09) | 0.725 | 1.13 (0.56–2.24) | 0.738 | |
Q3 (0.92–1.06) | 210 | 29 (13.8) | 1.47 (0.81–2.68) | 0.204 | 1.14 (0.58–2.23) | 0.706 | |
Q4 (≥ 1.07) | 210 | 67 (31.9) | 4.31 (2.52–7.36) |  < 0.001 | 2.37 (1.27–4.43) | 0.007 | |
 Pneumoniaa | Q1 (≤ 0.81) | 214 | 19 (8.9) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 212 | 14 (6.6) | 0.73 (0.35–1.49) | 0.381 | 0.70 (0.30–1.47) | 0.669 | |
Q3 (0.92–1.06) | 210 | 21 (10.0) | 1.14 (0.59–2.29) | 0.693 | 0.82 (0.39–1.70) | 0.818 | |
Q4 (≥ 1.07) | 210 | 48 (22.9) | 3.04 (1.72–5.38) |  < 0.001 | 1.44 (0.73–2.82) | 0.573 | |
 Urinary tract infectiona | Q1 (≤ 0.81) | 214 | 3 (1.4) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 212 | 6 (2.8) | 2.05 (0.51–8.30) | 0.315 | 1.67 (0.39–7.14) | 0.488 | |
Q3 (0.92–1.06) | 210 | 5 (2.4) | 1.72 (0.41–7.27) | 0.464 | 1.71 (0.38–7.63) | 0.458 | |
Q4 (≥ 1.07) | 210 | 8 (3.8) | 2.78 (0.73–10.65) | 0.134 | 2.32 (0.53–10.13) | 0.265 | |
 NIHSS ≥ 6 post dischargeb | Q1 (≤ 0.81) | 214 | 29 (14.1) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 212 | 30 (14.7) | 1.05 (0.61–1.83) | 0.856 | 1.22 (0.60–2.49) | 0.585 | |
Q3 (0.92–1.06) | 210 | 39 (19.4) | 1.47 (0.87–2.49) | 0.151 | 0.81 (0.40–1.62) | 0.546 | |
Q4 (≥ 1.07) | 210 | 67 (34.0) | 3.15 (1.93–5.14) |  < 0.001 | 1.63 (0.83–3.22) | 0.156 | |
 Dysfunction post discharge (Bathel ≤ 60)b | Q1 (≤ 0.81) | 214 | 81 (31.9) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 212 | 88 (41.5) | 1.11 (0.74–1.66) | 0.630 | 1.06 (0.64–1.79) | 0.818 | |
Q3 (0.92–1.06) | 210 | 114 (51.3) | 1.56 (1.04–2.32) | 0.030 | 1.22 (0.74–20.3) | 0.442 | |
Q4 (≥ 1.07) | 210 | 139 (66.2) | 2.72 (1.82–4.04) |  < 0.001 | 1.79 (1.06–3.01) | 0.029 |